A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
about
Pazopanib in the management of advanced soft tissue sarcomasSystemic analysis of gene expression profiles identifies ErbB3 as a potential drug target in pediatric alveolar rhabdomyosarcomaA phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.New therapeutic targets in soft tissue sarcoma.Effect of cediranib, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, in a mouse model of choroidal neovascularization.Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium.Cediranib for metastatic alveolar soft part sarcomaEpidemiology and therapies for metastatic sarcomaEmerging therapeutic targets for synovial sarcoma.Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastomaIntrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastomaTargeted therapies for advanced Ewing sarcoma family of tumors.Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors.Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials.Improving the outcome for children with cancer: Development of targeted new agents.A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium reportPhase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.The Current and Future Therapies for Human Osteosarcoma.Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma.Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report.Targeted therapy for soft tissue sarcomas in adolescents and young adults.Emerging therapeutic targets for soft tissue sarcoma.Ten challenges in the management of neuroblastoma.Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Headaches in brain tumor patients: primary or secondary?Targeted approaches to childhood cancer: progress in drug discovery and development.Investigational therapies for Ewing sarcoma: a search without a clear finding.A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials.Newer medical therapies for metastatic soft tissue sarcoma.Clinical Pharmacokinetics and Pharmacodynamics of Cediranib.A case study of personalized therapy for osteosarcoma.Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.Histology-Specific Uses of Tyrosine Kinase Inhibitors in Non-gastrointestinal Stromal Tumor Sarcomas.
P2860
Q26746205-FDA27697-E677-471B-B6DE-4B67788AC2E8Q28485467-7033AA37-C452-402C-8080-2D928BADEAE6Q33403207-A0BCF7F3-D4F0-447B-B90C-88EB7ED5FF5EQ34267924-8E9AF488-1069-4A6B-8EB5-FECBA9C05D5CQ34272439-CBA494D0-E7D3-4034-A5A8-B2DEF62089C7Q34543413-54191CD1-99AF-46E4-8E72-A0805B668BCCQ34651131-01D325FC-D7F7-4B86-AAF7-2F372F951C23Q34652142-F5817898-BBC6-4F18-9EAA-CDF77308B08BQ34660607-AF38FD00-A1FC-423D-AEFD-A5BCE2675DBBQ34757990-CA7F6031-AE46-414E-B5E9-39A0CCE956E5Q34983575-DBA9C679-0CAF-40E3-826F-E4F7054A2354Q35131527-FEAB88DE-EA3B-4244-B6CD-0C8AB1BD46CDQ35589492-6FD8AE83-EAE3-4A5F-AAA8-2F1AE746EE99Q35599819-09300EF1-F18C-491C-9DD5-4A6489E647FEQ35891218-C909629A-A696-460C-BA7E-39A8823E79E7Q36031619-3D3DE641-F34E-4437-B4F3-78216FB55CEAQ36226051-6B775874-080C-4746-9867-F33A337AE584Q36238795-173B8F1D-3E22-48BD-BDD7-26A46874AA76Q36243701-3FE2ACCF-07BE-470E-97EE-DAA57A011105Q36511158-E2E64355-37C9-43EB-A0D8-CB52F396AD46Q36514299-547474B0-6E29-45F7-99D7-4C333344FF8CQ36592628-97AAEE9D-6F75-4150-BEBA-419B9171E5B0Q36888962-F049E532-D795-452F-8C4A-E99715218B3CQ37085863-C84BEC6C-154C-43A1-8724-A0426892CA72Q37742014-D587D2FE-76EA-4604-A480-6948CB4B7D0DQ37869364-CBC0E0ED-05C8-4F0F-8F52-1ED7D8A5A3E6Q38029366-BFD4F2B9-2D82-4E9E-9250-60B057C3FE62Q38092618-90AA2FDE-F302-4D01-8333-6280204C166BQ38113988-AE5C2B2D-2459-4175-8517-CF058362125CQ38201750-5982B396-08FC-4B39-8F78-709BEEE792E9Q38404462-0EC56E27-C645-4981-A715-DB5C2C302F1FQ38778855-D0F1EB13-2E18-4D44-825C-6B82FC2EB10BQ38961012-8A590133-498C-4802-AF25-9355D91B3774Q39012067-680F52B9-35B4-4A72-8D1A-94D4654416DCQ39036230-9CC25078-45E1-4D56-8FD3-14B20EEAF601Q39176157-56D6D892-363C-4C24-9E34-65023E07666AQ39204706-B681732F-6F51-4540-8B2C-89B1630FD5E8Q39401628-186FD718-DADE-4FE7-A91B-63CDA77C2975Q39555847-504D1326-63DC-4DD4-B817-3CFF60FDEAF7Q39956277-30EC1B5C-A9CC-4157-96D8-4A66A82BDB08
P2860
A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@ast
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@en
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@nl
type
label
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@ast
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@en
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@nl
prefLabel
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@ast
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@en
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@nl
P2093
P2860
P921
P356
P1476
A phase 1 trial and pharmacoki ...... with refractory solid tumors.
@en
P2093
Anne Goodwin
Barbara Wenrich
Brigitte C Widemann
Elizabeth Fox
Frank M Balis
Kathryn H Brown
Marcelo Marotti
Marie Kromplewski
Meredith K Chuk
P2860
P304
P356
10.1200/JCO.2010.30.9674
P407
P577
2010-11-08T00:00:00Z